Bevacizumab (Avastin; Genentech Inc., South San Francisco, CA) and ranibizumab (Lucentis; Genentech Inc.)are the commonly used anti-VEGF drugs for these cases, and intravitreal injections of bevacizumab (IVB) and ranibizumab (IVR) have demonstrated efficacy in the treatment of stage 3 ROP (4–7). Here, VEGFA is linked to retinopathy of prematurity.